Developmental pharmacology and age-related pharmacokinetics — branching viva

Opening (candidate)

My first priority is the baby. I would support the airway and breathing with bag-mask ventilation, give naloxone titrated to respiratory effort, and call for senior paediatric and neonatal help. I would keep the infusion stopped and preserve the syringe and the original order, and I would check whether any other child is on the same protocol. Once the baby is safe I would escalate to the consultant, report the incident, and speak with the family honestly. [1] [5]

Branch A — The developmental framework

Examiner: Why did this neonate react so differently from an adult given the same drug per kilogram? [1]

Candidate: Children are not small adults. Every phase of drug handling — absorption, distribution, metabolism and excretion — changes with development, and the change is steepest in the first month of life. In this baby, distribution, metabolism and excretion all worked against the dose. Total body water is about 75 to 85 per cent in a term neonate versus about 60 per cent in an adult, and extracellular fluid is about 45 per cent versus 20 per cent, so the morphine distributed into a larger volume. Plasma protein binding is low, so the free fraction is higher. The blood-brain barrier is immature, so more of the active drug reached the central nervous system. [1] [4]

Branch B — Metabolism and excretion

Examiner: Walk me through the hepatic and renal maturation that prolonged this exposure. [2]

Candidate: Morphine is cleared mainly by glucuronidation through UGT2B7, which is markedly under-expressed in the first weeks of life. Phase II conjugation matures more slowly than phase I. On the renal side, glomerular filtration rate at birth is a fraction of adult values — about 20 to 40 mL per minute per 1.73 m² in the term neonate, and as low as 2 to 5 mL per minute per 1.73 m² in the very premature baby. Although it rises sharply over the first two weeks, it is still low in a 7-day-old. So the metabolites clear slowly as well. The combination of immature metabolism and immature excretion is why narrow-therapeutic-index drugs in the neonate have such a small safety window. [2] [5]

Branch C — The classic neonatal toxicities

Examiner: Name two other classic toxicities that illustrate the same developmental principle, and the enzyme or mechanism in each. [4]

Candidate: Grey-baby syndrome from chloramphenicol is the textbook example — UGT immaturity causes grey cyanosis, cardiovascular collapse and abdominal distension in neonates given adult-style cumulative exposure. Kernicterus is the second: UGT1A1 deficiency, which is normal in the neonate and underlies physiological jaundice, is compounded by drug-albumin displacement when sulphonamides or ceftriaxone displace bilirubin from albumin, raising the free bilirubin that crosses the immature blood-brain barrier. Both are PK-driven rather than PD-driven. [1] [4]

Branch D — CYP ontogeny

Examiner: What is the CYP3A7-to-CYP3A4 switch, and why does it matter? [2]

Candidate: CYP3A7 is the fetal form of the 3A subfamily and is dominant at birth. It is progressively replaced by the adult form CYP3A4 over the first weeks to months of life. This matters because CYP3A substrates — midazolam, ciclosporin, tacrolimus, and several chemotherapy agents — behave differently when metabolised by 3A7 than by 3A4. The classic teaching is that a neonate's apparent 'tolerance' to a 3A substrate may simply be that the drug is being cleared by a different enzyme with different kinetics. The same logic applies to the other CYP isoforms: CYP2D6 is active within days to weeks, CYP1A2 matures over months, and CYP2C9 and 2C19 follow intermediate trajectories. The first month of life is an ontogeny bottleneck. [2]

Branch E — The clearance overshoot

Examiner: Is the same dose-per-kilogram always safe in an older child? [7]

Candidate: No — and this is a high-yield trap. Per-kilogram clearance in mid-childhood can actually exceed adult clearance, because hepatic capacity and renal tubular secretion, normalised to body size, peak around early-to-mid childhood. A school-age child on standard mg/kg dosing of an anti-epileptic or an antibiotic can run subtherapeutic levels. That is why breakthrough seizures or treatment failure in a growing child should prompt a level check and dose revision, not just an assumption of non-adherence. [7]

Branch F — Prescribing safely

Examiner: How do you operationalise all of this at the bedside? [5]

Candidate: I confirm weight in kilograms — measured, never estimated — and the age variables: gestational age, postmenstrual age, postnatal age and corrected age. I look up the dose in a paediatric formulary — BNF for Children or Royal Children's Hospital Melbourne — rather than reproducing an adult dose from memory. I apply maturation adjustment for renally cleared drugs in the neonate and young infant, extending intervals based on postmenstrual and postnatal age. I cap weight-based doses at the adult maximum for larger or older children. I choose an age-appropriate formulation and check excipient safety in premature neonates. I require an independent double-check for high-risk medicines, and I set up therapeutic drug monitoring for narrow-therapeutic-index drugs. [1] [5]

Close

Confirm the baby is safe and monitored, preserve the evidence, report the incident, disclose honestly to the family with a clear plan, and lead a systems analysis that chooses strong actions — a paediatric-formulary order set, a hard independent double-check for high-risk infusions, and removal of adult morphine charts from paediatric areas — over a blame conversation. The teaching point is that a 'standard' adult dose produced toxicity because the child's clearance was immature; the system should make the developmentally appropriate dose the default. [1] [5]